
Camlin Fine Sciences (CAMLINFINE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
4.1B
Gross Profit
2.2B
52.72%
Operating Income
747.2M
18.04%
Net Income
1.1M
0.03%
Balance Sheet Metrics
Total Assets
20.2B
Total Liabilities
11.5B
Shareholders Equity
8.7B
Debt to Equity
1.31
Cash Flow Metrics
Revenue & Profitability Trend
Camlin Fine Sciences Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 16.7B | 16.0B | 16.7B | 14.0B | 11.7B |
Cost of Goods Sold | 8.5B | 9.4B | 8.3B | 7.7B | 5.9B |
Gross Profit | 8.2B | 6.6B | 8.4B | 6.3B | 5.8B |
Gross Margin % | 49.0% | 41.3% | 50.3% | 45.1% | 49.2% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 597.7M | 568.7M | 577.2M | 453.1M |
Other Operating Expenses | 4.2B | 2.6B | 3.8B | 2.6B | 2.1B |
Total Operating Expenses | 4.2B | 3.2B | 4.4B | 3.1B | 2.5B |
Operating Income | 1.4B | 713.3M | 1.6B | 1.1B | 1.6B |
Operating Margin % | 8.7% | 4.5% | 9.7% | 7.6% | 13.6% |
Non-Operating Items | |||||
Interest Income | - | 17.7M | 10.9M | 17.5M | 14.5M |
Interest Expense | 1.2B | 676.2M | 411.3M | 292.3M | 395.2M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 494.7M | -992.4M | 803.8M | 939.8M | 1.1B |
Income Tax | 665.0K | 56.3M | 405.7M | 336.1M | 397.4M |
Effective Tax Rate % | 0.1% | 0.0% | 50.5% | 35.8% | 37.8% |
Net Income | -1.6B | -1.0B | 398.1M | 603.7M | 653.6M |
Net Margin % | -9.5% | -6.6% | 2.4% | 4.3% | 5.6% |
Key Metrics | |||||
EBITDA | 2.6B | 1.2B | 2.0B | 1.8B | 1.9B |
EPS (Basic) | - | ₹-5.45 | ₹3.45 | ₹4.61 | ₹4.13 |
EPS (Diluted) | - | ₹-5.45 | ₹3.41 | ₹4.53 | ₹3.68 |
Basic Shares Outstanding | - | 170193218 | 167315188 | 140836278 | 123448779 |
Diluted Shares Outstanding | - | 170193218 | 167315188 | 140836278 | 123448779 |
Income Statement Trend
Camlin Fine Sciences Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.0B | 802.5M | 937.4M | 1.1B | 755.2M |
Short-term Investments | 901.2M | 9.7M | 14.5M | 209.8M | 476.3M |
Accounts Receivable | 3.3B | 2.9B | 3.0B | 3.0B | 2.7B |
Inventory | 5.3B | 5.1B | 5.7B | 3.7B | 3.2B |
Other Current Assets | 1.2B | 32.0M | 45.8M | 43.8M | 40.3M |
Total Current Assets | 11.8B | 10.0B | 10.9B | 8.9B | 7.9B |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.4B | 35.3M | 35.5M | 34.9M | 34.8M |
Goodwill | 1.1B | 1.1B | 1.2B | 1.3B | 1.1B |
Intangible Assets | 102.3M | 128.1M | 134.1M | 231.9M | 241.2M |
Long-term Investments | - | 0 | 18.3M | 34.0M | 997.0K |
Other Non-Current Assets | 57.7M | 54.1M | 45.1M | 156.6M | 171.3M |
Total Non-Current Assets | 8.4B | 9.5B | 9.7B | 9.1B | 6.9B |
Total Assets | 20.2B | 19.5B | 20.6B | 18.0B | 14.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.8B | 3.2B | 2.9B | 2.3B | 1.6B |
Short-term Debt | 3.9B | 3.3B | 3.8B | 2.4B | 2.7B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 159.4M | 327.8M | 94.5M | 38.7M | 8.2M |
Total Current Liabilities | 8.5B | 7.3B | 7.9B | 6.0B | 4.8B |
Non-Current Liabilities | |||||
Long-term Debt | 2.9B | 3.5B | 4.2B | 4.0B | 2.8B |
Deferred Tax Liabilities | 33.1M | 68.4M | 151.0M | 103.1M | 63.1M |
Other Non-Current Liabilities | 1.8M | 3.5M | 3.9M | 4.6M | - |
Total Non-Current Liabilities | 3.0B | 3.6B | 4.4B | 4.4B | 2.9B |
Total Liabilities | 11.5B | 10.9B | 12.4B | 10.4B | 7.7B |
Equity | |||||
Common Stock | 187.9M | 167.5M | 157.1M | 157.0M | 127.5M |
Retained Earnings | - | 2.3B | 3.0B | 2.3B | 1.5B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 8.7B | 8.6B | 8.2B | 7.7B | 7.1B |
Key Metrics | |||||
Total Debt | 6.8B | 6.8B | 8.0B | 6.5B | 5.5B |
Working Capital | 3.4B | 2.7B | 2.9B | 3.0B | 3.2B |
Balance Sheet Composition
Camlin Fine Sciences Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.6B | -992.4M | 803.8M | 939.8M | 1.1B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 2.8M | 90.0K | 23.6M | 73.9M | 45.3M |
Working Capital Changes | -784.2M | 316.7M | -1.4B | 41.7M | -659.3M |
Operating Cash Flow | -1.4B | 271.7M | -157.0M | 1.4B | 847.3M |
Investing Activities | |||||
Capital Expenditures | -424.5M | -600.2M | -1.4B | -2.1B | -838.7M |
Acquisitions | - | - | 0 | -655.4M | 0 |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -424.5M | -600.2M | -1.4B | -2.8B | -838.7M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | -281.3M | -138.5M | -7.1M | -54.2M |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 2.1B | -273.7M | 389.7M | 637.0M | 37.3M |
Free Cash Flow | -157.2M | 784.1M | -934.1M | -683.4M | 335.1M |
Net Change in Cash | 226.0M | -602.2M | -1.2B | -806.2M | 45.8M |
Cash Flow Trend
Camlin Fine Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
83.25
Forward P/E
16.31
Price to Book
4.96
Price to Sales
2.75
Profitability Ratios
Profit Margin
-8.34%
Operating Margin
9.38%
Return on Equity
5.71%
Return on Assets
4.56%
Financial Health
Current Ratio
1.40
Debt to Equity
77.88
Beta
0.38
Per Share Data
EPS (TTM)
₹2.86
Book Value per Share
₹47.98
Revenue per Share
₹96.25
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
camlinfine | 45.9B | 83.25 | 4.96 | 5.71% | -8.34% | 77.88 |
Asian Paints | 2.4T | 65.84 | 12.24 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 72.14 | 16.07 | 20.85% | 16.16% | 4.56 |
Balaji Amines | 49.8B | 32.68 | 2.69 | 7.80% | 11.11% | 0.55 |
Grauer & Weil | 43.7B | 27.77 | 4.65 | 18.02% | 13.85% | 1.26 |
Kingfa Science | 42.4B | 27.47 | 5.79 | 20.98% | 8.58% | 5.90 |
Financial data is updated regularly. All figures are in the company's reporting currency.